No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - International healthcare group Alliance Pharma announced the postponement of its preliminary results for the year ended 31 December on Monday.
The AIM-traded firm said the results, initially scheduled for 23 April, would now be delayed until early May.
It said it expected to provide an update on the publication date by 26 April.
Following an earlier announcement on 5 April, Alliance Pharma informed shareholders that despite the advanced stage of the audit process, its auditor, Deloitte LLP, had requested more time to finalise their work.
"Alliance reiterates that the details provided in the full year trading update on 29 January remain accurate," the board said in its statement.
At 1414 BST, shares in Alliance Pharma were down 1.63% at 36.25p.
Reporting by Josh White for Sharecast.com.
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.